1
|
Abstract
Organ-on-chip approaches could help researchers to better predict the toxicity of cancer immunotherapy drugs.
Collapse
|
2
|
Kerns SJ, Belgur C, Petropolis D, Kanellias M, Barrile R, Sam J, Weinzierl T, Fauti T, Freimoser-Grundschober A, Eckmann J, Hage C, Geiger M, Ng PR, Tien-Street W, Manatakis DV, Micallef V, Gerard R, Bscheider M, Breous-Nystrom E, Schneider A, Giusti AM, Bertinetti-Lapatki C, Grant HS, Roth AB, Hamilton GA, Singer T, Karalis K, Moisan A, Bruenker P, Klein C, Bacac M, Gjorevski N, Cabon L. Human immunocompetent Organ-on-Chip platforms allow safety profiling of tumor-targeted T-cell bispecific antibodies. eLife 2021; 10:e67106. [PMID: 34378534 PMCID: PMC8373379 DOI: 10.7554/elife.67106] [Citation(s) in RCA: 25] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2021] [Accepted: 08/10/2021] [Indexed: 12/13/2022] Open
Abstract
Traditional drug safety assessment often fails to predict complications in humans, especially when the drug targets the immune system. Here, we show the unprecedented capability of two human Organs-on-Chips to evaluate the safety profile of T-cell bispecific antibodies (TCBs) targeting tumor antigens. Although promising for cancer immunotherapy, TCBs are associated with an on-target, off-tumor risk due to low levels of expression of tumor antigens in healthy tissues. We leveraged in vivo target expression and toxicity data of TCBs targeting folate receptor 1 (FOLR1) or carcinoembryonic antigen (CEA) to design and validate human immunocompetent Organs-on-Chips safety platforms. We discovered that the Lung-Chip and Intestine-Chip could reproduce and predict target-dependent TCB safety liabilities, based on sensitivity to key determinants thereof, such as target expression and antibody affinity. These novel tools broaden the research options available for mechanistic understandings of engineered therapeutic antibodies and assessing safety in tissues susceptible to adverse events.
Collapse
Affiliation(s)
| | | | | | | | - Riccardo Barrile
- Emulate IncBostonUnited States
- Department of Biomedical Engineering, University of CincinnatiCincinnatiUnited States
| | - Johannes Sam
- Roche Pharma Research & Early Development, Roche Innovation Center ZurichSchlierenSwitzerland
| | - Tina Weinzierl
- Roche Pharma Research & Early Development, Roche Innovation Center ZurichSchlierenSwitzerland
| | - Tanja Fauti
- Roche Pharma Research & Early Development, Roche Innovation Center ZurichSchlierenSwitzerland
| | | | - Jan Eckmann
- Roche Pharma Research & Early Development, Roche Innovation Center MunichPenzbergGermany
| | - Carina Hage
- Roche Pharma Research & Early Development, Roche Innovation Center MunichPenzbergGermany
| | - Martina Geiger
- Roche Pharma Research & Early Development, Roche Innovation Center ZurichSchlierenSwitzerland
| | | | | | | | - Virginie Micallef
- Roche Pharma Research & Early Development, Roche Innovation Center BaselBaselSwitzerland
| | - Regine Gerard
- Roche Pharma Research & Early Development, Roche Innovation Center BaselBaselSwitzerland
| | - Michael Bscheider
- Roche Pharma Research & Early Development, Roche Innovation Center BaselBaselSwitzerland
| | | | - Anneliese Schneider
- Roche Pharma Research & Early Development, Roche Innovation Center ZurichSchlierenSwitzerland
| | - Anna Maria Giusti
- Roche Pharma Research & Early Development, Roche Innovation Center ZurichSchlierenSwitzerland
| | | | | | - Adrian B Roth
- Roche Pharma Research & Early Development, Roche Innovation Center BaselBaselSwitzerland
| | | | - Thomas Singer
- Roche Pharma Research & Early Development, Roche Innovation Center BaselBaselSwitzerland
| | | | - Annie Moisan
- Roche Pharma Research & Early Development, Roche Innovation Center BaselBaselSwitzerland
| | - Peter Bruenker
- Roche Pharma Research & Early Development, Roche Innovation Center ZurichSchlierenSwitzerland
| | - Christian Klein
- Roche Pharma Research & Early Development, Roche Innovation Center ZurichSchlierenSwitzerland
| | - Marina Bacac
- Roche Pharma Research & Early Development, Roche Innovation Center ZurichSchlierenSwitzerland
| | - Nikolce Gjorevski
- Roche Pharma Research & Early Development, Roche Innovation Center BaselBaselSwitzerland
| | - Lauriane Cabon
- Roche Pharma Research & Early Development, Roche Innovation Center BaselBaselSwitzerland
| |
Collapse
|